The International Council for Standardization in Haematology: 1964‐2021

Mackie, Ian; Erber, Wendy N.

doi:10.1111/ijlh.13637

Cited by 3 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 A quantitative, functional Clauss assay remains the gold standard for the investigation of suspected fibrinogen disorders and is widely available on automated coagulation analyzers; this measures the rate of conversion of clottable fibrinogen into fibrin, based on the thrombin time (TT), and is an indirect measurement of plasma fibrinogen concentrations. 8,10,11 There may be falsely lower fibrinogen levels when fibrin polymerization is slow, for example, due to delayed fibrinopeptide release. 10 Reduced fibrinogen concentrations by the Clauss assay are characteristic of dysfibrinogenemia, with the fibrinogen antigen concentrations typically also ranging from 2 to 4 g/L.…”

Section: Assays For Measuring Plasma Fibrinogen Concentrationmentioning

confidence: 99%

“…10 Reduced fibrinogen concentrations by the Clauss assay are characteristic of dysfibrinogenemia, with the fibrinogen antigen concentrations typically also ranging from 2 to 4 g/L. 11 The presence of fibrinogen/fibrin degradation products (FDPs) or direct thrombin inhibitors (e.g., dabigatran or bivalirudin) in a plasma sample may cause falsely reduced fibrinogen concentrations, while high levels of heparin (usually exceeding 2U/mL and neutralization capacity) can also interfere with the results of the Clauss assay, causing false low values. Typical results in fibrinogen disorders are shown in ►Table 2.…”

Section: Assays For Measuring Plasma Fibrinogen Concentrationmentioning

confidence: 99%

See 1 more Smart Citation

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies

Undas

2024

Semin Thromb Hemost

View full text Add to dashboard Cite

Congenital and acquired fibrinogen disorders often have heterogeneous clinical phenotypes and are challenging from a laboratory perspective. Fibrinogen determination using the Clauss method remains the gold standard, while the reproducibility and significance of the thrombin time and the reptilase time are limited. Molecular testing for causative mutations in fibrinogen genes is now recommended to confirm the diagnosis of congenital fibrinogen disorders. Research assays are used to evaluate alterations to fibrin formation and properties of plasma and purified fibrinogen-derived clots, characterized by fiber thickness, the number of branches, and pore sizes. Fibrin clot permeability (permeation, porosity) using a hydrostatic pressure system represents the most commonly used method for evaluating fibrin network density. Reduced clot permeability, which denotes the reduced size of an average pore in the network, results in tighter fibrin networks, typically associated with impaired susceptibility to lysis, leading to a thrombotic tendency. Biophysical properties of fibrin clots are largely assessed using rheometry, with atomic force microscopy and nanorheology being increasingly used in disease states. Thromboelastography and thromboelastometry, a simple modification of rheometry, have been used, mainly in intensive care units, for more than 50 years. Given growing evidence for altered fibrin clot properties in diseases with elevated risk of venous and arterial thromboembolism and in some bleeding disorders, further work on standardization and validation of the assessment of fibrin clot characteristics is needed. This review summarizes the current methods used to evaluate fibrinogen abnormalities in both diagnostic and research laboratories.

show abstract

Section: Assays For Measuring Plasma Fibrinogen Concentrationmentioning

confidence: 99%

Section: Assays For Measuring Plasma Fibrinogen Concentrationmentioning

confidence: 99%

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies

Undas

2024

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…The “Carol Briggs‐Smalley Scholarship” was established in 2015 to honour the significant contributions the late Carol Briggs made to laboratory haematology and is awarded to a medical technologist or laboratory scientist. The “Sam Machin ICSH Scholarship”, established in 2021, recognizes the outstanding contributions made by the late Professor Sam Machin to the practice of laboratory haematology particularly during his 14‐year term as ICSH Chair (2007–2020) 7 . This Scholarship is offered to a Haematologist‐in‐Training or junior Haematologist.…”

mentioning

confidence: 99%

“…Over the 60 years, the ICSH has been chaired by Jan Spaander (1963)(1964)(1965)(1966)(1967)(1968)(1969)(1970)(1971)(1972)(1973)(1974)(1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982), S. Mitchell Lewis (1982Lewis ( -1994, Onno van Assendelft (1995-2005), Samuel Machin (2007-2020) and currently Wendy Erber (since 2020). [5][6][7] ICSH membership is comprised of Corporate (industry representatives) and Affiliate Members; the latter being representatives of national, regional and international haematology associations and societies. The ICSH holds annual meetings (the "General Assembly") where ICSH activities are discussed.…”

mentioning

confidence: 99%

“…The Board includes a Chair, past‐Chair, Vice‐Chair (Haemostasis), Treasurer, Scientific Secretary and corresponding liaison members with the ISLH and WHO. Over the 60 years, the ICSH has been chaired by Jan Spaander (1963–1982), S. Mitchell Lewis (1982–1994), Onno van Assendelft (1995–2005), Samuel Machin (2007–2020) and currently Wendy Erber (since 2020) 5–7 . ICSH membership is comprised of Corporate (industry representatives) and Affiliate Members; the latter being representatives of national, regional and international haematology associations and societies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The International Council for Standardization in Haematology: 60 years (1963–2023)

Erber

2023

Int J Lab Hematology

Self Cite

View full text Add to dashboard Cite

Hemostasis Testing in the Emergency Department: A Narrative Review

Thonon,

Van Nieuwenhove,

Thachil

et al. 2024

Semin Thromb Hemost

View full text Add to dashboard Cite

Routine laboratory screening is typically performed at initial evaluation of the vast majority of presentations to the emergency department (ED). These laboratory results are crucial to the diagnostic process, as they may influence up to 70% of clinical decisions. However, despite the usefulness of biological assessments, many tests performed are inappropriate or of doubtful clinical relevance. This overutilization rate of laboratory testing in hospitals, which represents a significant medical–economic burden, ranges from 20 to 67%, with coagulation tests at the top of the list. While reviews frequently focus on nonintensive care units, there are few published assessments of emergency-specific interventions or guidelines/guidance to date. The aim of this review is to highlight current recommendations for hemostasis evaluation in the emergency setting with a specific analysis of common situations leading to ED admissions, such as suspected venous thrombosis or severe bleeding. We revisit the evidence related to the assessment of patient's hemostatic capacity based on comprehensive history taking and physical examination as well as best practice recommendations for blood sample collection to ensure the reliability of results. This review also includes an examination of various currently available point of care tests and a comprehensive discussion on indications, limitations, and interpretation of these tests.

show abstract

The International Council for Standardization in Haematology: 1964‐2021

Cited by 3 publications

References 4 publications

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies

Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies

The International Council for Standardization in Haematology: 60 years (1963–2023)

Hemostasis Testing in the Emergency Department: A Narrative Review

Contact Info

Product

Resources

About